ATE526951T1 - Zubereitung zur getakteten freisetzung - Google Patents

Zubereitung zur getakteten freisetzung

Info

Publication number: ATE526951T1
Authority: AT; Austria
Prior art keywords: rpm; tablets; composition; predetermined time; therapeutically active
Prior art date: 2001-04-10

Application number

AT02733207T

Other languages

English (en)

Inventor

Dilip Shantilal Shanghvi

Nitin Bhalachandra Dharmadhikari

Yashoraj Rupsinh Zala

Satish C Khanna

Original Assignee

Sun Pharma Advanced Res Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-10

Filing date

2002-04-09

Publication date

2011-10-15

2002-04-09 Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526951T1 publication Critical patent/ATE526951T1/de

Links

239000013543 active substance Substances 0.000 abstract 2
239000012736 aqueous medium Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000007922 dissolution test Methods 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
230000008961 swelling Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Dermatology (AREA)

AT02733207T 2001-04-10 2002-04-09 Zubereitung zur getakteten freisetzung ATE526951T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN325MU2001		2001-04-10
PCT/IN2002/000107 WO2002080887A2 (en)	2001-04-10	2002-04-09	Timed pulse release composition

Publications (1)

Publication Number	Publication Date
ATE526951T1 true ATE526951T1 (de)	2011-10-15

Family

ID=11097233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02733207T ATE526951T1 (de)	2001-04-10	2002-04-09	Zubereitung zur getakteten freisetzung

Country Status (12)

Country	Link
US (1)	US20040156900A1 (de)
EP (1)	EP1377276B1 (de)
JP (1)	JP5328071B2 (de)
AT (1)	ATE526951T1 (de)
CA (1)	CA2443632C (de)
DK (1)	DK1377276T3 (de)
ES (1)	ES2373873T3 (de)
MX (1)	MXPA03008997A (de)
PT (1)	PT1377276E (de)
RU (1)	RU2324475C2 (de)
WO (1)	WO2002080887A2 (de)
ZA (1)	ZA200307551B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7964216B2 (en) *	2001-01-12	2011-06-21	Sun Pharma Advanced Research Company Limited	Spaced drug delivery system
WO2004108067A2 (en) *	2003-04-03	2004-12-16	Sun Pharmaceutical Industries Limited	Programmed drug delivery system
US8029822B2 (en)	2003-05-22	2011-10-04	Osmotica Kereskedelmi és Seolgáltató KFT	Rupturing controlled release device having a preformed passageway
US20060165745A1 (en) *	2005-01-21	2006-07-27	Yiwen Chew	Sustained release tablets for treatment of aqueous environment and methods for making the same
US20090169622A1 (en) *	2007-12-27	2009-07-02	Roxane Laboratories, Inc.	Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US20100159001A1 (en) *	2008-12-19	2010-06-24	Cardinal John R	Extended-Release Pharmaceutical Formulations
JP5471569B2 (ja)	2010-02-18	2014-04-16	株式会社リコー	レーザ駆動装置、光走査装置、画像形成装置及びレーザ駆動方法
RU2444371C1 (ru) *	2010-09-15	2012-03-10	Общество с ограниченной ответственностью "Озон" (ООО "Озон")	Комбинированное гипотензивное средство
RU2483717C2 (ru) *	2010-11-22	2013-06-10	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтическая композиция для лечения диабета (варианты)
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
WO2012094636A2 (en)	2011-01-07	2012-07-12	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
CN104349773A (zh)	2012-01-06	2015-02-11	埃尔舍利克斯治疗公司	用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt)	2012-01-06	2022-01-11	Anji Pharma (Us) Llc	Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
CN109758431A (zh) *	2017-11-09	2019-05-17	郑州泰丰制药有限公司	一种盐酸二甲双胍片及其制备方法
CN109010298B (zh) *	2018-08-31	2020-10-27	迪沙药业集团有限公司	一种二甲双胍格列吡嗪复方组合物及其制备方法
CN120225199A (zh) *	2022-11-21	2025-06-27	持田制药株式会社	口服固体制剂

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1228757B (de) *	1962-06-28	1966-11-17	Haessle Ab	Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) *	1962-09-12	1966-04-19	Parke Davis & Co	Controlled release dosage form containing water-swellable beadlet
US4252786A (en) *	1979-11-16	1981-02-24	E. R. Squibb & Sons, Inc.	Controlled release tablet
ZA822995B (en) *	1981-05-21	1983-12-28	Wyeth John & Brother Ltd	Slow release pharmaceutical composition
US4681583A (en) *	1982-12-20	1987-07-21	Alza Corporation	System for dispersing drug in biological environment
JPS60241871A (ja) *	1984-05-16	1985-11-30	Ajinomoto Co Inc	アスパルテ−ム含有崩壊錠剤の製造法
GB8518301D0 (en) *	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
CH668187A5 (de) *	1986-08-07	1988-12-15	Ciba Geigy Ag	Therapeutisches system mit systemischer wirkung.
US4874388A (en) *	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system
US4976967A (en) *	1987-08-03	1990-12-11	Merck & Co., Inc.	Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4891223A (en) *	1987-09-03	1990-01-02	Air Products And Chemicals, Inc.	Controlled release delivery coating formulation for bioactive substances
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
GB8913889D0 (en) *	1989-06-16	1989-08-02	May & Baker Ltd	New compositions of matter
EP0408496A3 (en) *	1989-07-12	1992-07-01	Ciba-Geigy Ag	Solid dosage form for pharmaceutical substances
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5474784A (en) *	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
IT1246382B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5226902A (en) *	1991-07-30	1993-07-13	University Of Utah	Pulsatile drug delivery device using stimuli sensitive hydrogel
PT100944B (pt) *	1991-10-10	2000-02-29	Alza Corp	Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
US5209746A (en) *	1992-02-18	1993-05-11	Alza Corporation	Osmotically driven delivery devices with pulsatile effect
US5260068A (en) *	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
US5260069A (en) *	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
US5358941A (en) *	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
GB9408117D0 (en) *	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
JP4072597B2 (ja) *	1994-12-27	2008-04-09	ナムローゼ・フェンノートシャップ・オルガノン	持続性製剤
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH11513989A (ja) *	1995-10-27	1999-11-30	メルクエンドカンパニーインコーポレーテッド	成長ホルモン分泌促進薬の湿式造粒製剤
IT1276130B1 (it) *	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6153632A (en) *	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
DE19718012C1 (de) *	1997-04-29	1998-10-08	Jenapharm Gmbh	Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) *	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
US6004582A (en) *	1997-05-30	1999-12-21	Laboratorios Phoenix U.S.A, Inc.	Multi-layered osmotic device
KR20010012104A (ko) *	1997-06-11	2001-02-15	디르크 반테	(+)- 또는 (-)-시사프라이드의 즉시 방출 ｐＨ-비의존적 고체 제형
CA2290969C (en) *	1997-07-01	2004-02-17	Pfizer Products Inc.	Delayed-release dosage forms of sertraline
DE69814122T2 (de) *	1997-10-09	2004-03-18	Dexcel Pharma Technologies Ltd.	Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
CA2312990C (en) *	1997-12-08	2008-04-29	Bristol-Myers Squibb Company	Novel salts of metformin and method
WO1999047128A1 (en) *	1998-03-19	1999-09-23	Bristol-Myers Squibb Company	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099862A (en) *	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6096341A (en) *	1998-10-30	2000-08-01	Pharma Pass Llc	Delayed release tablet of bupropion hydrochloride
WO2000059481A1 (en) *	1999-04-06	2000-10-12	Pharmaquest Ltd.	PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6632451B2 (en) *	1999-06-04	2003-10-14	Dexcel Pharma Technologies Ltd.	Delayed total release two pulse gastrointestinal drug delivery system
JP2003504415A (ja) *	1999-07-20	2003-02-04	メルクエンドカムパニーインコーポレーテッド	持続放出性薬物分散剤輸送装置
JP2001055322A (ja) *	1999-08-18	2001-02-27	Tanabe Seiyaku Co Ltd	パルス放出型製剤
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
US6491949B2 (en) *	2000-01-14	2002-12-10	Osmotica Corp.	Osmotic device within an osmotic device
US6352721B1 (en) *	2000-01-14	2002-03-05	Osmotica Corp.	Combined diffusion/osmotic pumping drug delivery system
AR026148A1 (es) *	2000-01-21	2003-01-29	Osmotica Argentina S A	Dispositivo osmotico con pasaje preformado que aumenta de tamano
US6376682B1 (en) *	2000-02-01	2002-04-23	Takama System, Ltd.	Compound with α-glucosidase inhibiting action and method for producing the same
GB0025208D0 (en) *	2000-10-13	2000-11-29	Euro Celtique Sa	Delayed release pharmaceutical formulations
US7964216B2 (en) *	2001-01-12	2011-06-21	Sun Pharma Advanced Research Company Limited	Spaced drug delivery system
WO2004108067A2 (en) *	2003-04-03	2004-12-16	Sun Pharmaceutical Industries Limited	Programmed drug delivery system
ATE551051T1 (de) *	2003-09-19	2012-04-15	Sun Pharma Advanced Res Co Ltd	Orales arzneimittelabgabesystem
US10213387B2 (en) *	2003-09-19	2019-02-26	Sun Pharma Advanced Research Company Ltd.	Oral drug delivery system
ES2403069T3 (es) *	2005-02-22	2013-05-13	Sun Pharma Advanced Research Company Ltd	Composición oral de liberación controlada que contiene levetiracetam
US8187633B2 (en) *	2005-11-03	2012-05-29	Sun Pharma Advanced Research Company Limited	Controlled release coated tablets having prolonged gastric retention
US9217369B2 (en) *	2012-03-15	2015-12-22	Siemens Aktiengesellschaft	Compressor inlet manifold for a gas turbine engine

2002
- 2002-04-09 US US10/474,360 patent/US20040156900A1/en not_active Abandoned
- 2002-04-09 PT PT02733207T patent/PT1377276E/pt unknown
- 2002-04-09 AT AT02733207T patent/ATE526951T1/de not_active IP Right Cessation
- 2002-04-09 RU RU2003132699/15A patent/RU2324475C2/ru not_active IP Right Cessation
- 2002-04-09 EP EP02733207A patent/EP1377276B1/de not_active Expired - Lifetime
- 2002-04-09 CA CA2443632A patent/CA2443632C/en not_active Expired - Fee Related
- 2002-04-09 MX MXPA03008997A patent/MXPA03008997A/es active IP Right Grant
- 2002-04-09 DK DK02733207.1T patent/DK1377276T3/da active
- 2002-04-09 JP JP2002578926A patent/JP5328071B2/ja not_active Expired - Fee Related
- 2002-04-09 ES ES02733207T patent/ES2373873T3/es not_active Expired - Lifetime
- 2002-04-09 WO PCT/IN2002/000107 patent/WO2002080887A2/en not_active Ceased
2003
- 2003-09-29 ZA ZA200307551A patent/ZA200307551B/en unknown

Also Published As

Publication number	Publication date
PT1377276E (pt)	2011-12-30
WO2002080887A3 (en)	2002-11-28
RU2324475C2 (ru)	2008-05-20
JP2004525162A (ja)	2004-08-19
CA2443632A1 (en)	2002-10-17
EP1377276A2 (de)	2004-01-07
MXPA03008997A (es)	2004-02-12
US20040156900A1 (en)	2004-08-12
WO2002080887A2 (en)	2002-10-17
ZA200307551B (en)	2004-02-11
RU2003132699A (ru)	2005-02-10
JP5328071B2 (ja)	2013-10-30
EP1377276B1 (de)	2011-10-05
DK1377276T3 (da)	2012-01-02
CA2443632C (en)	2011-05-03
ES2373873T3 (es)	2012-02-09

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MXPA03008997A (es)	2004-02-12	Composicion de liberacion por impulso temporizado.
KR950702409A (ko)	1995-07-29	방출 조절 모르핀 제제(controlled release morphine preparation)
Bussemer et al.	2003	Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system
HRP940979A2 (en)	1997-02-28	New diffusion-osmotic controlled drug-release pharmaceutical preparation and a process for the preparation of the same
Krögel et al.	1999	Floating or pulsatile drug delivery systems based on coated effervescent cores
CA2375714A1 (en)	2000-12-14	Delayed total release two pulse gastrointestinal drug delivery system
ES2901522T3 (es)	2022-03-22	Sistemas de suministro de fármacos gastrorretentivos osmóticos autorregulados
DK1021171T3 (da)	2003-08-25	Lægemiddelfremførelsessystem til forsinket, fuldstændig frigivelse gastrointestinalt
Bussemer et al.	2003	Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles
CA2561109A1 (en)	2005-11-03	Gastric retention system
ATE268593T1 (de)	2004-06-15	Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
IS2156B (is)	2006-11-15	Settar bensensúlfonamíðafleiður sem forlyf fyrir COX-2 tálma, aðferð til þess að búa þær til, lyfjasamsetningar sem innihalda þær og notkun þeirra við framleiðslu lyfja
BR0308761A (pt)	2005-01-11	Formulação farmacêutica para o ingrediente ativo budesonida
BR0211317A (pt)	2004-12-14	Sistema para a liberação controlada de uma droga por meio de retenção gástrica
WO2004108067A3 (en)	2005-07-28	Programmed drug delivery system
PE20050286A1 (es)	2005-06-13	Formulacion de multiparticulas que comprenden oxicodona
CA2346341A1 (en)	2001-11-05	Encapsulated chemicals for use in controlled time release applications and methods
BR0109378A (pt)	2003-06-03	Pelìculas oralmente consumìveis de rápida dissolução contendo uma resina de permuta de ìon como um agente de mascaramento de sabor
TNSN01123A1 (fr)	2005-11-10	Formes posologiques nouvelles a liberation controlee
BR0009919B1 (pt)	2009-01-13	sistema de teste para a verificaÇço de um poÇo de sondagem, e mÉtodo de verificaÇço de um poÇo.
EP2260836A3 (de)	2012-02-01	Schnellfreisetzende Tablette mit beschichtetem, wirkstoffhaltigem Kern und umgebender Schicht als Geschmacksbarriere
NO970610L (no)	1997-03-21	Sammensetning for selektiv frigjöring av en aktiv ingrediens
NZ270748A (en)	1995-12-21	Sustained release dosage form of alfuzosin hydrochloride coated with a ph-dissolution dependent polymer
EP1048297A3 (de)	2002-05-08	Verwendung von Polyethylenglykol zur Verminderung von Darmgasen, Krämpfen und Anorektalereizung
EP2098225B8 (de)	2011-06-22	Geschmacksunterdrückungssystem für nicht weichgemachte Arzneimittel